Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
- Resource Type
- Article
- Source
- In
The Lancet Diabetes & Endocrinology March 2024 12(3):162-173 - Subject
Primary Research Articles - Language
- ISSN
- 2213-8587